Company news

Aldeyra Therapeutics, Inc. news in 2021

Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease

December 19, 2021

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance

November 8, 2021

Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease

November 1, 2021

Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights

October 27, 2021

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights

October 20, 2021

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

August 4, 2021

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

August 3, 2021

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights

July 28, 2021

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma

July 19, 2021

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes

June 30, 2021

Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights

May 5, 2021

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights

April 28, 2021

Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

April 27, 2021

Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock

April 26, 2021

Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

April 26, 2021

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial

April 25, 2021

Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights

March 10, 2021

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights

March 3, 2021

Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design

February 3, 2021

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 19, 2021

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

January 12, 2021

Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

January 12, 2021

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

January 6, 2021

Calls in 2021

Decks in 2021